US 11,654,191 B2
Vaccine for intradermal application against PCV2 and PRRS virus infection
Melanie Sno, Venlo (NL); Maarten Hendrik Witvliet, Oostrum (NL); and Vicky Fachinger, Bad Soden (DE)
Assigned to Intervet Inc., Madison, NJ (US)
Appl. No. 16/86,701
Filed by Intervet Inc., Madison, NJ (US)
PCT Filed Mar. 22, 2017, PCT No. PCT/EP2017/056781
§ 371(c)(1), (2) Date Sep. 20, 2018,
PCT Pub. No. WO2017/162720, PCT Pub. Date Sep. 28, 2017.
Claims priority of application No. 16161994 (EP), filed on Mar. 23, 2016.
Prior Publication US 2019/0099480 A1, Apr. 4, 2019
Int. Cl. A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 39/02 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/0021 (2013.01); A61K 39/0241 (2013.01); A61K 2039/521 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/54 (2013.01); A61K 2039/70 (2013.01); C12N 2750/10034 (2013.01); C12N 2770/10034 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A single-dose vaccine comprising in combination a non-replicating immunogen of porcine circovirus type 2 (PCV2) and a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, wherein the vaccine is administered intradermally for use in prophylactically treating an animal against an infection of PCV2, PRRS virus, or both PCV2 and PRRS virus.